Disclosed herein is the use of a first therapeutic agent of [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2Hquinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment of a condition in a mammal selected from the group consisting of acute myocardial infarction, stable angina, chronic stable angina, transient ischemic attacks, strokes, peripheral vascular disease, preeclampsia/eclampsia, deep venous thrombosis, embolism, disseminated intravascular coagulation and thrombotic cytopenic purpura, thrombotic and restenotic complications following invasive procedures resulting from angioplasty, carotid endarterectomy, post CABG (coronary arteryl bypass graft) surgery, vascular graft surgery, stent placements and insertion of endovascular devices and prosthesis, wherein the medicament is for administration in combination with a second therapeutic agent which is selected from the group consisting of betrixaban, a specific inhibitor of factor IXa, a specific inhibitor of factor XI, a specific inhibitor of factor XIa, a specific inhibitor of factor VIIa, YM-150, Daiichi DU-176b, N-{ (1R)-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-phenylethyl} -1H-indole-6-carboxamede, apixaban, rivaroxaban, otamixaban, razaxaban, AZD0837, RB2006, ximelagatran, dabigatran, bivalirudin, argatroban, phenocoumarol, synthetic pentasaccharides, such as fondaparinux, idraparinux, biotinylated idraparinux； abciximab, eptifibatide, tirofiban, dipyridamole, Aggrenox, cilostazol, ifetroban, isogrel, furegrelate, resveratrol, ozagrel, an anticoagulant agent and an antiplatelet agent.
